The use of antibody-enzyme conjugates directed at tumorassociated antigens to achieve site-specific activation of prodrugs to potent cytotoxic species, termed "antibodydirected enzyme prodrug therapy" (ADEPT), has attracted considerable interest since the concept was first described in 1987. Prodrug forms of both clinically used anticancer agents and novel cytotoxic compounds have been developed to take advantage of potential prodrug-generating technology employing a variety of enzymes with widely differing substrate specificities. A particular advantage of the ADEPT approach is that it may allow the use of extremely potent agents such as nitrogen mustards and palytoxin, which are too toxic to be readily used in conventional chemotherapy. Preliminary studies using an antibody-enzyme conjugate constructed with a bacterial enzyme and a murine monoclonal antibody not only have established the value of the ADEPT technique, but also have highlighted the potential problem of immunogenicity of proteins of nonhuman origin. This problem has been tackled in the first instance by the use of immunosuppressive agents, but long-term solutions are being investigated in the development of second-generation ADEPT systems, including the development of human antibody-human enzyme fusion proteins and catalytic antibodies. Such improvements, coupled with further refinement of the prodrug-drug element of the system and the wide variety of antibody-enzyme-drug combinations available, should mean that ADEPT-based approaches will form an important element of the search for the anticancer drugs of the future. [J Natl Cancer Inst 1996;88:153-65]
The advent of monoclonal antibody technology in the 1970s was thought at the time to herald the fruition of the search for the "magic bullet" first proposed by Ehrlich in the early years of this century (/) . In practice, however, this goal has remained elusive, inasmuch as many obstacles have presented themselves and have proved to be very difficult to overcome. To date, there have been numerous attempts to improve the cytotoxicity of the antibody "missiles" by attaching a variety of "warheads" to them-e.g., cytotoxic drugs such as doxorubicin or methotrexate, toxins such as ricin A-chain or Pseudomonas exotoxin, and radioisotopes (2) . Recently, enzymes capable of activating prodrugs to active drugs have been the focus of considerable interest and form the subject of this review.
For any form of antibody-mediated targeting to be successful, it is axiomatic that there must be selective expression of the target antigen by the tumor cells. This provides the first barrier to overcome, for the only well-characterized tumor-specific antigens described to date are the idiotypic determinants on the surface immunoglobulins of B-cell lymphomas (3) . Tissuespecific antigens are also known, e.g., prostate-specific antigen (PSA), but have yet to be exploited to any great extent in targeted immunotherapy regimens. Many antigens, e.g., oncofetal antigens such as carcinoembryonic antigen (CEA) or placental alkaline phosphatase, and other potential targets such as growth factor receptors are present in elevated levels in tumor tissue, but most, if not all, appear to be found to a greater or lesser extent in other tissues. These limitations have not prevented exploitation of the better characterized tumor-associated antigens (e.g., CEA) as targets for therapy, even though it is also well documented that tumor cells exhibit considerable antigenic heterogeneity (4) (5) (6) . Tumor cells may express varying levels of antigen, and some cells may not express the target antigen at all, such that a single monoclonal antibody conjugate targeted at a tumor mass will not bind to all the cells present, although other antibodies may be used to target alternative antigens on such cells. This is a disadvantage for immunoconjugates constructed using cytotoxic moieties that need to bind to the target cells and be internalized to exert their effect; however, the problem may be overcome to some extent by the use of antibody "cocktails" in which a mixture of antibodies aimed at two or more discrete antigens is used in noncompetitive combination (7) .
The ability of conjugates to gain access to the target cells is also essential, yet there is ample evidence that antibodies penetrate tumors poorly (8, 9) . Thus, the best access is at the tumor periphery, and cells located near the center of the tumor mass may be inaccessible to immunoconjugates, even though they may express antigen. Cells in such inaccessible anoxic zones may be quiescent but possess the ability to regrow if exposed to a supply of oxygen and nutrients as a result of more vulnerable cells in oxic zones being killed. For this reason, radioimmunoconjugates have been extensively studied, because the emissions from the isotopes used clinically are capable of penetrating several cell layers, killing cells distal from where the antibody is localized. Although this approach is attractive, in practice the relatively low tumor uptake of the radioimmunoconjugate may require large patient exposures, giving rise to dose-limiting myelosuppression and necessitating the use of autologous bone marrow grafts {10).
Antibody-Directed Enzyme Prodrug Therapy as an Alternative Strategy
An alternative strategy that has recently been the subject of considerable interest is the use of antibodies as vectors for enzymes capable of activating a nontoxic drug precursor, termed a "prodrug," to a potently cytotoxic moiety. This approach, which has been termed "antibody-directed enzyme prodrug therapy" (ADEPT) (11), or "antibody-directed catalysis" (72) , offers the potential to overcome most of the problems associated with the use of drug or toxin immunoconjugates described above. The system is shown by the diagram in Fig. 1 . An antibody-enzyme conjugate is injected and allowed to localize at the tumor while clearing from the rest of the tissues. After a suitable interval, the prodrug is administered; while remaining innocuous to the normal tissues, it is converted to a cytotoxic form by enzyme localized within the tumor tissue. Being of low molecular weight, the active drug can diffuse to adjacent tissues, providing a bystander effect, although this may be of questionable benefit if the released drug is relatively stable and can diffuse back into the circulation. It is implicit in the ADEPT approach that the antigen to which the antibody-enzyme conjugate is targeted must remain extracellular; thus, secreted antigen that accumulates in the tumor interstitial spaces may assist in achieving high levels of conjugate at the tumor site. Although shed antigen present in the circulation will act as a competitor with the tumor site for binding of target antigen, there is evidence that tumor localization of conjugate can occur in the face of circulating antigen unAnti body-enzyme conjugate less levels of the latter are particularly high (11). Another source of antigen may arise from the lysis of tumor cells following the active drug release from the prodrug by the action of the enzyme in the antibody-enzyme conjugate bound to cell surfaces. However, it is unlikely that there is any antibody-enzyme conjugate in the circulation at that time; thus, such antigen release may not be problematic except in situations where repeat cycle(s) of therapy are administered before this antigen is cleared from the body.
A further advantage of ADEPT is that a single enzyme molecule has the potential to cleave many prodrug moleculesup to 800 mol/mol of enzyme per second in the case of the benzoic acid mustard substrates of carboxypeptidase G2 (13)-providing an amplification effect giving high levels of drug localized at the tumor; this may be an important advantage in the clinic, in view of the typically low localization of immunoconjugates in humans (14) . There is also some evidence that high levels of drug generated at the surface of tumor cells are more effective than equivalent concentrations of free drug (75) . The prodrug is an integral component of ADEPT systems and requires careful design in its own right. An ideal prodrug would be one with a large differential in cytotoxicity between drug and prodrug, which is a good substrate for the enzyme under physiologic conditions and for which there is no mammalian homologue capable of performing the same reaction. The use of human enzymes requires qualification of the latter statement, as discussed below. Equal cytotoxicity of the released active drug toward proliferating and quiescent cells is also desirable if residual deposits of viable but nonproliferating cells with the potential for outgrowth are to be eradicated. Once formed, it would be desirable for the drug to have a very short half-life, limiting the possibility of escape of active drug back into the circulation and access to healthy tissue. Development of drug resistance may limit the effects of conventional active drugs produced from prodrugs; thus, the nitrogen mustard group of compounds has tended to be the most commonly used group of active drugs for ADEPT because these compounds are not cell cycle specific, can be hydrolyzed to nontoxic forms, can kill both well-oxygenated and hypoxic cells, and cells develop only low levels of resistance to them (16) . The potential release of the active drug into the circulation is conceivable after tumor cell lysis, but most drugs proposed for ADEPT systems are potent alkylating or intercalating agents and are likely to remain bound irreversibly to intracellular targets.
In selecting an enzyme, one would look for activity under physiologic conditions, low immunogenicity, and little or no equivalent endogenous enzyme in humans. The enzyme needs to have a high specific activity, because the amounts that can be delivered by antibody vectors are limited; however, the definition of optimal enzyme kinetics is clear cut and, as we shall see, under certain circumstances, a low kcat (i.e., the turnover rate of enzyme, which is expressed as number of moles of substrate utilized per mole of enzyme per second) may be preferable to a higher kcat (17) . If a human enzyme is selected in an attempt to develop a nonimmunogenic conjugate, it will probably need to be an intracellular enzyme so that endogenous enzyme does not give rise to activation of the prodrug in the blood. When coupled to an antibody, the enzyme must localize efficiently at the tumor, and the development of immune responses to non-human enzymes is undesirable, since localization of the conjugate is likely to be drastically reduced upon readministration after the onset of an immune response (18) and there will be a risk of hypersensitive reactions. However, immunosuppressive drug regimens designed to extend the time window before the onset of the human immune response observed in patients (19) have been developed to counteract this problem (20) . The gains obtained using such approaches in animal models have been modest, but they may be sufficient to allow two or three repeat courses of an ADEPT cycle.
An important factor in early stages of the development of an ADEPT system is the production of an antibody-enzyme conjugate without loss of antigen-binding and enzymatic activities. The techniques and heterobifunctional agents typically used are analogous to those developed for use in the construction of immunotoxins. An important requirement for conjugates prepared for use in ADEPT is that the linkage should be stable, since a period of up to or greater than 72 hours may elapse between the administration of conjugate and the administration of prodrug, in order to allow unbound conjugate to clear from the circulation. For this reason, conjugation chemistry based on thioether linkages has been virtually universally adopted.
A number of experimental ADEPT systems have been developed, with a range of different enzymes, and it is thus convenient to categorize them by class of enzyme (Table 1) .
Enzymes used for ADEPT systems to date include carboxypeptidases G 2 and A, alkaline phosphatase, glycosidases, penicillin amidase, P-lactamase, and cytosine deaminase. All are at a very early stage of development, with only the carboxypeptidase G 2 system having been tested clinically to date. Typically, these systems have been tested in nude mouse models with human xenograft targets. These represent probably the best models currently available, but they have clear limitations. For example, the subcutaneous tumor implant is nonmetastatic and, therefore, does not represent the typical clinical situation, where the treatment of advanced metastatic disease is likely to be the early target, with the eventual prospect of moving to minimal residual disease following surgery to debulk the tumor. Moreover, the levels of tumor localization achievable in mice far exceed those that have been found clinically with radiolabeled antibodies. The fact that .nude mice are immunodeficient also prevents consideration of the problem of immunogenicity, an issue of considerable importance, as has been revealed by early clinical studies (21, 22) . Once a workable system has been established,.there is likely to be a lengthy development stage while all aspects of the system are reevaluated and optimized. Typically, the necessary development work will include the synthesis of improved prodrugs, substitution of human enzymes for bacterial enzymes where possible, the adoption of chimeric or human antibodies and fragments thereof, the generation of nonimmunogenic clearing systems, and the develop- ment of fusion proteins or bifunctional catalytic antibodies with suitable binding specificity for tumor-associated antigens. With such a range of parameters to be optimized, the development of ADEPT systems is clearly complex and likely to be time-consuming and expensive.
Enzymes and Prodrugs Used in Currently Available ADEPT Systems
Carboxypeptidase G2
The first ADEPT system was proposed by Bagshawe (25) in 1987; it used carboxypeptidase G2 (CPG2), which was originally isolated as a methotrexate-degrading enzyme from Pseudomonas species and subsequently cloned in Escherichia coli (24) , to cleave a deactivating glutamate moiety from a benzoic acid mustard (25) . This remains probably the best characterized system and is the only system to date for which pilot clinical studies have commenced (19, 21, 22) . The initial prodrug to be synthesized was 4-[A'^V-bis(2-chloroethyl)amino]benzoyl-L-glutamic acid from which CPG2 cleaves the glutamic acid to yield 4-[/vVV-bis(2-chloroethyl)amino]benzoic acid ( Fig. 2, A) . Subsequently, modified versions were developed with one or both of the 2-chloroethyl arms replaced by more reactive 2-mesyloxyethyl moieties (Fig. 2, B ) (25) . The mono-(2-mesyloxyethyl) (MMC1) compound was more cytotoxic and a slightly better substrate for the enzyme than the bis(2-chloroethyl) compound, but the bis(2-mesyloxyethyl) form was too reactive and rapidly hydrolyzed in the absence of enzyme (25, 26) . The enzyme conjugate-prodrug combination was initially tested in vitro using the human chorionic gonadotropin (hCG)-expressing JAR choriocarcinoma cell line; it was found to give greater than 100-fold differential toxicity between drug or prodrug plus enzyme (IC50 [i.e., the concentration required to kill 50% of treated cells compared with untreated controls] = 20 UJW) and prodrug (IC 50 = >800 \iM) (27) . In antitumor studies using the hCG-expressing human CC3 choriocarcinoma xenograft model in nude mice, the combination of W14 (anti-hCG) F(ab')2-CPG 2 conjugate followed 72 hours later by the MMC1 prodrug resulted in complete eradication of established CC3 xenografts when prodrug was administered as a three-times-divided dose of 10 mg/kg (total dose, 30 mg/kg) at 16-hour intervals from 72 hours (1327). In contrast, weekly intravenous injections of daily divided doses of methotrexate (5 mg/kg), hydroxyurea (50 mg/kg), dactinomycin (7.5 |ag/kg), or cytarabine (20 mg/kg) failed to retard tumor growth, whereas the MMC1 prodrug and the W14 F(ab')2-CPG 2 conjugate produced a pronounced growth delay of more than 50 days (27) .
When the same two-phase system was applied to the CEAexpressing human LS174T colon carcinoma model, using a conjugate constructed with the F(ab')2 fragment of A5B7 anti-CEA antibody, it proved to be less effective in that minimal growth delays were seen (28) . This was probably because of the much slower clearance of conjugate from the blood in this model compared with that in the choriocarcinoma. In the latter case, high levels of circulating antigen probably form immune complexes, leading to accelerated clearance; however, much lower levels of antigen are present in the circulation of CEA-expressing tumors (29) , and the clearing effect of free antigen is thus not apparent. As a result, a second galactosylated clearing antibody, SB43, which enzymatically inactivated CPG 2 , was used to remove unbound conjugate from the circulation, making the system a three-phase approach (30). The galactosylated antibody has a relatively short half-life in the circulation because it is rapidly cleared by hepatic galactose receptors; consequently, it can react with the CPG2 conjugate in the circulation but is not extravasated sufficiently to reach the conjugate in the extravascular compartment. This situation should avoid the problem of clearing antibody reaching and inactivating the tumor-bound antibody-enzyme conjugate (30). When the three-phase system was tested against the same model, prolonged growth delays of up to 10-15 days, compared with untreated controls, were seen with the MMC1 compound and, to a lesser extent, with the bischloro compound (28) . Using a superficially identical model, Blakey et al. (31) were subsequently able to achieve growth delay of 10-15 days without recourse to clearing antibody. The principal difference between the experiments lay in the method of tumor implantation: Solid tumor fragments were used in the earlier work, whereas injection of a cell suspension was done in the later experiments.
In an alternative approach to the use of clearing antibody, Melton et al. (32) demonstrated enhanced tumor localization of antibody-enzyme conjugate when administered with tumor necrosis factor-a (TNF-a) in the murine E3 thymoma model. Coadministration of 1.5 (ig TNF-a with conjugate led to a twofold increase in tumor localization and only transient increases in normal tissue localization. It is possible that this system could be used in combination with the galactosylated clearing antibody because the two approaches are complementary: TNF-a increases tumor localization of conjugate without significantly affecting blood levels, and galactosylated antibody markedly decreases blood levels without affecting tumor localization. Galactosylated antibody increases the ratios of tumor to normal tissue without affecting overall tumor uptake, whereas TNF-a provides a mechanism for achieving higher initial tumor uptake. Similar effects can be induced by the administration of drugs that modify blood flow, which essentially appear to act by inducing localized production of TNF-a (33) .
The preclinical studies using the colon carcinoma xenograft model and the MMC1 compound were deemed sufficiently encouraging to justify a limited clinical trial in patients with advanced metastatic, poorly differentiated colon or rectal cancer (1921, 22) . Initial dose escalation studies using the monomesyl benzoic acid mustard prodrug showed that doses from 200 up to 2500 mg/m 2 , given as six or 12 divided doses over a 3-day period, were well tolerated. A total of four male patients aged 55-70 years, all of whom had undergone extensive conventional chemotherapy (principally with fluorouracil), subsequently went on to receive 20 000 U/m 2 A5B7 (anti-CEA) F(ab')2-CPG 2 conjugate, a small proportion of which was I25 I labeled to facilitate confirmation of tumor localization by gamma camera imaging. SB43 clearing antibody was administered 36-48 hours later as a 3-to 5-hour infusion, typically followed by MMC1 (1200-3000 mg/m 2 ) once measured serum enzyme levels were less than 0.02 U/mL. The serum levels of CEA and a second tumor antigen, 19-9, fell in all patients by 10-15 days after therapy; in two cases, there were objective responses in the reduction in size of liver metastases. A patient who had gross hepatomegaly and ascites became free of jaundice and ascites, although liver size was not reduced. Other subjective responses included relief of pain, and three patients gained weight and reported improved health. Adverse effects included the development of antibodies to both components of the conjugate, and the two patients receiving the highest doses of prodrug developed severe myelosuppression, although this was reversible once prodrug administration was ceased. The antibody responses developed within 10-12 days, limiting the treatment effectively to a single cycle; however, this time window may be extended by the use of the immunosuppressive drug cyclosporine (20) . The development of myelosuppression appears to be due to the relatively long half-life of the active drug, which can diffuse out of the tumor and back into the circulation, indicating that more reactive drugs with shorter physiologic half-lives are desirable. The results of the pilot clinical study are encouraging, if one bears in mind the advanced state of the disease of the patients in the study, and provide ample justification for further development of the system. Carboxypeptidase A Huennekens and co-workers (15,34-37) described a system in which carboxypeptidase A (CPA) is used to cleave the alphacarboxyl alanine residue from methotrexate-a-alanine. When human lung adenocarcinoma cells were exposed to conjugate consisting of CPA coupled to KS1/4 antibody, followed by washing and addition of prodrug, the IC 50 of methotrexate-aalanine decreased approximately sixfold from 8.9 x 10" 6 M to 1.5 x 10" 6 M after 48 hours of incubation. With prolonged incubation, the toxicity of methotrexate-a-alanine approached that of methotrexate (i.e., about 2 x 10" 9 M) (15) . It is thus clear that the enzyme turns over the substrate rather slowly, although the authors suggested that methotrexate generated in intimate contact with the cells in this way seems to be more cytotoxic than the equivalent concentration of free methotrexate. A study of the theoretical aspects of ADEPT by Yuan et al. (17) suggested that a low turnover rate may not be disadvantageous because the rate-limiting step is diffusion of drug from the capillaries to the extravascular tumor cells; however, this observation must be set against the need to generate sufficient drug to exert the desired cytotoxic effect. The most important factor in attaining tumor-specific activation may be the achievement of high tumor-to-normal tissue localization ratios and rapid reaction of the active drug to prevent its loss back into the circulation. If these issues can be resolved, then the use of an enzyme with a high turnover and affinity for substrate would seem to be ideal because the level of prodrug reaching the tumor is unlikely to match that present in blood. It seems likely, however, that the relatively poor kinetics of this enzyme with the first-generation prodrug are unlikely to lead to a workable system in vivo, and a number of groups (38J9) recently described the synthesis of potentially better substrates based on methotrexate. No animal studies have been reported for the CPA/methotrexate-a-alanine system, and the likelihood of activation of prodrug by endogenous CPA remains as a possible disadvantage of this approach. In view of the development of resistance to methotrexate and the high levels of drug needed to achieve maximal effect (40) , it is questionable whether this is a suitable drug for ADEPT applications, particularly when the kinetics of the enzyme are relatively poor.
Aminopeptidase
Smal et al. (41) recently described the synthesis of a series of 2-aminoacyl methotrexate prodrugs designed to be substrates for pyroglutamate aminopeptidase or D-aminopeptidase. The cytotoxicity of the prodrug plus enzyme in vitro did not approach that of methotrexate alone and required high levels of enzyme to achieve any selective cell kill, suggesting that this is not a prac-tical working system in its present form. To date, the production and testing of antibody-enzyme conjugates have not been described, and it is difficult to envisage the delivery of amounts of enzyme activity equivalent to those used in the experiments described, using an antibody vector.
Alkaline Phosphatase
A number of groups have presented evidence that alkaline phosphatase can be used to activate a range of prodrugs (Fig. 3) , taking advantage of alkaline phosphatase's relative lack of substrate specificity. Human alkaline phosphatase, in conjunction with a humanized monoclonal antibody, may result in a conjugate with reduced immunogenicity by comparison with bacterial enzyme conjugates. However, endogenous alkaline phosphatase is widely distributed in the body and is likely to activate prodrug in normal tissues, suggesting that this system is primarily of academic interest. To test the concept of using alkaline phosphatase, Senter and co-workers used calf intestinal alkaline phosphatase to cleave phosphate groups from etoposide phosphate (42) (43) (44) , mitomycin C phosphate (42), doxorubicin phosphate (45) , and phenol mustard phosphate (46) and have reported antigen-specific cytotoxicity in vitro and growth delays in vivo with human colon carcinoma xenograft models; conjugates constructed with an irrelevant antibody showed greatly reduced growth delays, indicating that nonspecific uptake of conjugate is relatively low compared with the uptake of conjugate with specificity for the appropriate antigen. The use of this enzyme does not address the question of possible immunogenicity, but it would be expected to have kinetic properties similar to those of the human homologue. Other researchers (47,48) described similar systems using other antibodies directed toward human colon cancer antigens. Perhaps the most interesting of these describes the use of a bifunctional antibody capable of binding both alkaline phosphatase and the CD30 antigen; the purpose was to enable the production of conjugates by immunologic interaction rather than by chemical coupling (48) . Such an approach requires an enzyme that is not catalytically inactivated by the antibody binding to it; in this instance, the authors were fortunate that the binding of alkaline phosphatase by bispecific intact antibody or F(ab')2 fragment did not adversely affect the enzyme's ability to activate the phosphorylated mitomycin C prodrug.
Glycosidases
A number of groups have described ADEPT systems based on glycosidases (Fig. 4) . Roffler and co-workers (49£0) used (3-glucuronidase from Escherichia coli to remove a glucuronide from hydroxyaniline mustard. This system takes advantage of the fact that hydroxyaniline mustard is rapidly detoxified by hepatic enzymes by conversion to the glucuronide form (51, 52) . In certain animal tumors, hydroxyaniline mustard glucuronide was activated back to hydroxyaniline mustard by elevated levels of endogenous (3-glucuronidase to give site-specific cytotoxicity (57) , although attempts to use this system in humans were not successful (53).
Escherichia coli (3-glucuronidase, coupled to monoclonal antibody 12.8 that binds to human colon carcinoma cells, has been shown to be capable of activating hydroxyaniline mustard glucuronide in vitro in an immunologically specific manner, with an IC50 for the enzymatically produced hydroxyaniline mustard of 34 \iM compared with about 1890 \\M for hydroxyaniline mus- tard glucuronide. It was found (49) that high levels of endogenous (3-glucuronidase did not appear to cause marked activation of hydroxyaniline mustard glucuronide, suggesting that the prodrug does not gain access to native (3-glucuronidase. An alternative system employing (3-glucuronidase is based on the conversion of epirubicin-glucuronide to epirubicin (54) . Epirubicin is another drug for which the glucuronide is a natural metabolite (55) , and indeed the preliminary experiments of Haisma et al. (54) used the urine of patients undergoing epirubicin therapy as a source of epirubicin-glucuronide; 35% of excreted epirubicin was present in the glucuronide form. Epirubicin-glucuronide was found to be 100-fold to 1000-fold less toxic than epirubicin; IC50 values were greater than 20 \x.M, compared with the range in values of 0.003-0.2 \JM for epirubicin. Epirubicin-glucuronide was found to be a reasonably good substrate for Escherichia coli (3-glucuronidase, with K m (i.e., Michaelis constant) of 10 \xM, but the kcat was only about 0.05 s" 1 . The rate of internalization of the conjugate, an important consideration addressed in very few publications, was shown to be low; 90% of bound conjugate remained on the cell surface after 24 hours of incubation at 37 °C. However, it was also found that the enzyme was inhibited by the presence of serum proteins, losing about 50% of its activity after 24 hours of incubation (54) .
A further class of glucuronidyl prodrugs based on anthracycline compounds has been synthesized, although this class of prodrugs has not as yet been tested in vitro or in vivo in an ADEPT context using enzymatic activation (56) . These compounds use an interesting benzylcarbamate self-immolative linker between a galactose or glucuronide and the primary amine group of daunosamine, the carbohydrate constituent of daunorubicin and doxorubicin. The prodrug form shows markedly reduced cytotoxicity against murine L1210 leukemia cells (IC 50 for prodrug of >1 |ig/mL compared with IC 50 for daunorubicin of 0.02 (ig/mL), but it is not yet known whether these compounds are substrates for glucuronidase or galactosidase.
One further glycosidase application is that reported by Bamias and Epenetos (57), who used |3-glucosidase to hydrolyze the cyanogenic glucoside amygdalin, resulting in the liberation of cyanide. They found that the combination of a specific conjugate and amygdalin is almost as effective as potassium cyanide, whereas a nonspecific conjugate plus amygdalin was much less effective in vitro (57) . However, this system does not appear to have been further developed.
Penicillin Amidase
A doxorubicin phenoxyacetamide compound and a similarly modified melphalan compound were shown by Kerr et al. (58) to be substrates for penicillin-V amidase isolated from Fusarium oxysporum. The generalized mechanism for the activation of these prodrugs is illustrated in Fig. 5 . The doxorubicin phenoxyacetamide prodrug was 20-fold to 80-fold less toxic to cells than doxorubicin, depending on the cell line, whereas the corresponding melphalan compound showed greater deactivation, being 100-fold to 1000-fold less toxic than melphalan. Antigen-specific activation of doxorubicin by a saturating amount of cell-bound antibody-enzyme conjugate was shown to result in a 7.5-fold to 12.5-fold increase in toxicity of doxorubicin phenoxyacetamide; however, no pronounced increase in the toxicity of melphalan phenoxyacetamide in the presence of antigen-specific conjugate was found, indicating that the rate of turnover of the prodrug by penicillin-V amidase was too slow to generate a cytotoxic concentration of this drug. The activation of phenylacetamido derivatives of doxorubicin and melphalan by Escherichia coli penicillin-G amidase has also been demonstrated (58£9). With this enzyme, there was a 20-fold differential in vitro between drug (IC 50 = 5 \i.M) and prodrug (IC 50 = 100 \iM) for the melphalan compounds. Senter and co-workers (60) described an alternative substrate for penicillin-G amidase based on one of the most potent toxins known, palytoxin, which is obtained from tropical coelenterates of the genus Palythoa (61) . The phenoxyacetamide form of palytoxin is at least 1000-fold less toxic than the unmodified toxin (60); however, in the presence of antigen-bound penicillin-G amidase-antibody conjugate, the prodrug was as toxic as the active drug.
This system is of particular interest for a number of reasons. First, the toxin has an IC50 of about 10"
12 M, compared with 1CT 6 -10~7 M for agents such as doxorubicin or mitomycin C. If limited amounts of prodrug can reach tumor cells, this enhanced potency may be very valuable, although there is also the possibility that minimal residual levels of antibody-enzyme conjugate present in normal tissues may give rise to systemic conversion of the prodrug and consequent toxicity. A second potential advantage of palytoxin is that it is a surface-active agent, binding to cell surface receptors and creating a pore in cell membranes (62) . All other ADEPT systems described to date are based on the generation of agents with intracellular sites of action, providing an added barrier for the activated drug to cross, and the additional complication of the possible development of drug resistance where prodrug forms of clinically used drugs are used. In contrast, palytoxin may provide a route by which multidrug resistance may be circumvented. Experiments using cells with acquired resistance to conventional cytotoxic drugs such as doxorubicin, mitomycin C, and fluorouracil showed that there was no decrease in cytotoxicity of palytoxin in the same cell lines (60) . Against these advantages, however, must be set the caveat that the IC 50 of 10"
9 M for the prodrug is likely to be several orders of magnitude lower than the K m for the enzyme; the lowest K m reported for an ADEPT system to date is about 10" 6 M (13) . At the maximum dose levels possible, therefore, the enzyme turnover rate is likely to be minimal. In an in vitro model, where saturating levels of bound antibodyenzyme conjugate can be readily achieved and incubation times prolonged, such a low turnover rate may not be crucial, as evidenced by the reported enhancement of cytotoxicity of the prodrug in the presence of enzyme (67); however, to reproduce this situation in vivo would not be straightforward, and it is likely that the toxicity due to the prodrug would become dose limiting well before pronounced site-specific activation of prodrug occurred.
(3-Lactamase
A further enzyme developed for ADEPT is the (3-lactamase from Enterobacter cloacae 256A (63) . This enzyme has the advantage that it is highly specific for p-lactams and is not endogenous to the mammalian system; it is therefore subject to minimal interference from inhibitors, enzyme substrates, or endogenous enzyme systems. The generalized reaction scheme is illustrated in Fig. 6 . The cytotoxic moiety is attached to the cephalosporin as a C-3' substituent and is cleaved by fi-lactamase to generate free cephalosporin and active drug. The cephalosporin component is known to be nontoxic to mammalian cells. Alexander et al. (64) described the synthesis of cephalosporin nitrogen mustards, ranging from bis-chloroethylamine to phenylene diamine mustard. All were relatively good substrates for Enterobacter cloacae pVlactamase; their K m values were in the range of 40-180 \\M, and their kcat values ranged from 120 to 510 s~'. In vivo antitumor studies with the Escherichia coli TEM-2 enzyme coupled to L6 antibody and using a 7-(phenylacetamido) cephalosporin mustard prodrug have been reported by Vrudhula and colleagues (65, 66) , and pronounced growth delays of established human H2981 lung adenocarcinoma xenografts were achieved using a single injec- tion of conjugate (1 mg antibody component per kilogram), followed 96 hours later by three separate injections of 62 mg/kg prodrug at 4-hour intervals. Shepherd et al. (12) described a similar system using a prodrug consisting of a vinca alkaloid, mercapto-substituted desacetylvinblastine, attached to the C-3' position of the cephalosporin nucleus. The active drug is a potent mitotic spindle elongation factor inhibitor; thus, it would be a cell cyclespecific agent, with the disadvantage of having differential activity against proliferating or quiescent cells. A fivefold difference in cytotoxicity between drug and prodrug was found during a 6-hour exposure to drug or prodrug; however, prodrug plus a tumor-specific antibody (anti-CEA)-enzyme conjugate had the same IC 50 as active drug against CEA-expressing cells. These in vitro studies were subsequently extended by Meyer et al. (67) , who showed that an anti-CEA Fab'-P-lactamase conjugate had essentially identical kinetic properties to the free enzyme (K m = -160 \iM; kcat = -170 s" 1 ) for the desacetylvinblastine hydrazine prodrug. In vivo experiments in nude mice have shown that the prodrug, in combination with an anti-CEA Fab'-P-lactamase conjugate, can suppress the growth of established LS174T tumors when it is administered as three complete cycles of conjugate followed 96 hours later by prodrug and allowing 72 hours between repeat cycles (68). These conditions gave virtually total eradication of tumors 60-80 days after implantation, therapy having commenced 9 days after implantation. Prodrug or conjugate alone was ineffective, whereas active drug alone showed an effect intermediate between that seen in untreated controls and that seen in animals receiving the full ADEPT cycle. An irrelevant antibody conjugate plus prodrug was more efficacious than active drug alone, presumably because of nonspecific entrapment of the conjugate at the tumor site. LS174T cells co-express three distinct tumor-associated antigens (i.e., CEA, TAG72, and KS1/4), and conjugates directed at each of these antigens gave virtually identical growth delays (Fig. 7) .
These antitumor studies are notable as the first to use multiple cycles of therapy (albeit in an immunocompromised host) and are difficult to compare with the results obtained by researchers who have used single doses of conjugate and divided doses of prodrug. The development of immune responses in an immunocompetent host would be expected to limit the opportunity for administration of repeat cycles (20) . The benefit of the repeat cycles is also difficult to judge because results with a single-cycle method were not presented, and, although the pharmacokinetics of the conjugate were studied, this was for a single dose of conjugate, so that the value of subsequent doses is unknown.
Cytosine Deaminase
Senter et al. (69) reported that antibody-linked cytosine deaminase can convert the clinically used antifungal agent 5-fluorocytosine into the known antitumor drug fluorouracil. An obvious advantage of this system is that both prodrug and active drug have known pharmacology and pharmacokinetics. In an in vitro cytotoxicity assay against H2981 lung adenocarcinoma cells, 5-fluorocytosine plus an L6 (H2981-specific) antibodycytosine deaminase conjugate showed cytotoxicity identical to that of fluorouracil, giving an IC50 of 20 |iA/. In contrast, 5-fluorocytosine alone or combined with a nonspecific antibodycytosine deaminase conjugate showed little or no toxicity at concentrations up to 20 UJV/. Somewhat surprisingly, in vivo biodistribution studies using radiolabeled conjugate have failed to demonstrate convincing specific accumulation of L6-cytosine deaminase conjugate in H2981 tumor-bearing mice (70) ; other studies using L6 as vector for alkaline phosphatase have shown some evidence of localization, although the percentage of the injected dose localized in tumor was not great (1.0% at 24 hours) (43) . More recently, however, the same workers (71) described further experiments, using the same conjugate, in which the levels of enzyme activity in excised tissues were determined; by this criterion, the conjugates appeared to give levels of localization comparable to those reported for other conjugates, at about 5% injected dose per gram of tissue at 48 hours after administration. These experiments also used a second antibody-clearing system analogous to that described by Sharma et al. (30) , albeit without galactosylation of the antibody. This antibody did not enzymatically inactivate cytosine deaminase, and, although increasing levels of clearing antibody did reduce levels of cytosine deaminase activity in tumor, the effect was much less pronounced than the removal of conjugate from blood. This difference in clearance rates gave rise to greatly enhanced tumor-to-tissue ratios for cytosine deaminase, greater than 40:1 for tumor to blood, 72 hours after conjugate administration, when clearing antibody was injected at 24 hours (72). The enhanced tumor-to-tissue ratios for cytosine deaminase manifestly led to selective conversion of 5-fluorocytosine to fluorouracil in tumor, with a 17-fold increase in the area under the curve from the targeted therapy compared with systemic drug administration. The ratio of 5-fluorocytosine to fluorouracil for tissues, including blood, liver, and kidney, was in the range of 13-29:1, whereas the ratio of 5-fluorocytosine to fluorouracil for tumor was 0.33:1. This is an impressive enhancement, and antitumor studies with this system will be very interesting.
Nitroreductase
Although the reductase class of enzymes has the disadvantage that these enzymes require a cofactor (usually NADH [i.e., nicotinamide adenine dinucleotide, reduced] or NADPH [i.e., nicotinamide adenine dinucleotide phosphate, reduced]) for activity, such enzymes nevertheless offer some prospect of being useful in ADEPT applications. The discovery that the Walker carcinoma was uniquely sensitive to the drug 5-(aziridin-l-yl)-2,4-dinitrobenzamide (CB1954) raised hopes that this drug might be of value in the clinic, but clinical trials failed to demonstrate its value. The sensitivity of the Walker carcinoma was found to be due to the presence of an enzyme, a form of DT-diaphorase, which is capable of bioactivating CB1954 by specific reduction of the 4-nitro group to form 5-(aziridin-1-yl)-4-hydroxylamino-2-dinitrobenzamide (73) . Certain strains of bacteria have also been shown to be sensitive to CB1954, and a bacterial enzyme from Escherichia coli has been isolated and purified (74) . Its sequence is virtually identical to that of the "classical" nitroreductase found in Salmonella typhimurium and that in an induced trinitrotoluene-degrading enzyme isolated from Enterobacter cloacae (75) . Although work on this enzyme is at a preliminary stage, in an in vitro cytotoxicity assay using V79 Chinese hamster cells, there was a 10 000-fold differential toxicity between prodrug plus enzyme plus NADH compared with prodrug plus NADH or prodrug plus enzyme (75) .
Fusion Proteins and Catalytic Antibodies
An attractive element of the ADEPT concept is that it should be possible to use protein-engineering techniques to produce fusion proteins containing both antigen-binding and enzymatic activities. Model compounds consisting of a mouse Fab fused with nucleases or polymerases were reported some time ago (76) . Such constructs could be produced in relatively high yield and with a greater homogeneity of conjugate by comparison with current chemical-linking techniques, where yields are relatively low and the product is ill-defined in terms of its homogeneity (77) . The first such fusion protein developed specifically for an ADEPT application was that reported by Bosslet et al. (78) . It consists of human p-glucuronidase fused to the C H domain of BW431, a high-avidity anti-CEA antibody, humanized by complementarity-determining region (CDR) grafting. The protein thus produced has antigen affinity very similar to that of the parent antibody, retains enzymatic activity, and is produced as roughly 50% each of monomeric and dimeric forms; the latter are present as a mixture of noncovalently and covalently linked (via an interchain disulfide bridge) forms (78) . The human enzyme has a low pH optimum of 4.5 but retains about 20% of its maximum activity at pH 7.0, the reported pH of the tumor microenvironment, although the kcat under these conditions is about 0.8 s~', about 20-fold greater than that of Escherichia coli P-glucuronidase (54) . This differential may help to protect against nonspecific activation of prodrug in the circulation.
In vivo studies in nude mice have shown that very high tumor-to-blood or tumor-to-tissue specificity ratios (>100:1) can be obtained 7 days after an injection of 20 mg/kg fusion protein (79) . Administration of doxorubicin glucuronide prodrug (250 mg/kg) at day 7 resulted in therapeutic effects superior to those obtained by conventional chemotherapy, without detectable toxicity. Thus, the rapid clearance of the fusion protein appears to offset the relatively poor kinetic properties of the enzyme. The fact that a human enzyme is used in conjunction with a humanized antibody suggests that this fusion protein may have low immunogenicity in humans. However, this hypothesis has yet to be established as reality.
Goshorn et al. (80) described the construction of a Bacillus cereus P-lactamase II-single-chain antibody fusion protein. The antibody used, L6, recognizes an antigen expressed on breast, colon, lung, and ovarian carcinomas. The fusion protein is produced by Escherichia coli in an active form that does not require refolding and retains immunologic and enzymatic properties similar to those of an equivalent chemically linked conjugate (80) . Other workers have constructed a similar fusion based on an anti-c-erbB2 antibody (81) , and in a further variation, (3-lactamase has been substituted for one antigen-binding arm in a chimeric murine/human antibody, the remaining antigen-binding arm being specific for placental alkaline phosphatase (82) .
A further refinement made possible by protein-engineering techniques is to make a bifunctional antibody in which one arm possesses an enzyme-mimicking catalytic function. Using combinatorial libraries of human antibodies as sources of the components offers the possibility of producing virtually nonimmunogenic constructs, although it is likely that this will not avoid the development of anti-idiotype responses. Although catalytic antibody technology is still in relative infancy, the first catalytic antibody capable of activating prodrugs (in this instance, a chloramphenicol monoester rather than an anticancer agent) has already been described (83) . More relevantly, Campbell et al. (84) described a catalytic antibody capable of mimicking cytosine deaminase by converting 5-fluorocytosine to fluorouracil. The catalytic antibody has a K m of 218 (iM but a kcat of only 0.03 min"'. The value for the K m compares favorably with that of the enzyme isolated from Baker's Yeast (K m = 2.5 mM for cytosine), but the kcat seems to be very low indeed (kcat of the yeast-derived enzyme calculated as -40 s~') (69) . Although this first catalytic antibody has, on the face of it, insufficient turnover capacity to be of value, it nevertheless represents an encouraging development, and it seems probable that systems capable of matching current chemically linked conjugates will be developed in due course as the technology matures.
In summary, it is apparent that there is a rich diversity of potential enzyme and prodrug combinations for use in ADEPT applications, and it is highly probable that additional examples will materialize. As yet, there are relatively little in vivo data available, and although what does exist provides exciting grounds for encouragement, it is already becoming clear that a number of crucial issues need to be resolved. The specificity of uptake of conjugate needs to be improved, either by selectively increasing tumor uptake using vascular permeability-enhancing drugs or by constructing conjugates with improved pharmacokinetic properties. Ultimately, the latter approach will probably be the more important one, since the ultimate aim of all workers will be to minimize the need for additional clearing steps or treatments to modify tumor vasculature, in order to simplify as far as possible what is a relatively complex system. The development of immune responses against the enzyme component in particular remains an obstacle, which may not be simply resolved by the use of a human enzyme, given that such enzymes are, by definition, endogenous. The use of immunosuppressive drugs may provide a partial remedy, but more sophisticated solutions are desirable. Protein-engineering techniques are, however, rapidly developing. They hold the promise of the development of nonimmunogenic conjugates derived from human antibodies and enzymes in the medium to long term, while in the shorter term there is the alternative possibility of masking the immunogenicity of conjugates by modification with polyethylene glycol or other similar polymers (85) . There is a long way to go, but the pace of progress is rapid and everquickening. We hope that it will not be too long before we see ADEPT systems forming an important element of the armament of the clinical oncologist.
